{"id":790,"date":"2017-02-26T19:12:39","date_gmt":"2017-02-26T19:12:39","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?page_id=790"},"modified":"2026-03-17T11:43:56","modified_gmt":"2026-03-17T15:43:56","slug":"lonafarnib-pre-clinical-drug-supply-program","status":"publish","type":"page","link":"https:\/\/www.progeriaresearch.org\/de\/lonafarnib-pre-clinical-drug-supply-program\/","title":{"rendered":"Pr\u00e4klinisches Arzneimittelversorgungsprogramm f\u00fcr Lonafarnib"},"content":{"rendered":"

[et_pb_section fb_built=\u201d1\u2033 fullwidth=\u201don\u201d disabled_on=\u201doff|off|off\u201d _builder_version=\u201d4.16\u2033 border_width_bottom=\u201d55px\u201d border_color_bottom=\u201d#29327a\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_fullwidth_header _builder_version=\u201d4.18.1\u2033 title_font=\u201d||||||||\u201d title_font_size=\u201d55\u2033 background_color=\u201d#29327a\u201d background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg\u201d background_position=\u201dcenter_left\u201d custom_padding=\u201d9vw||9vw||true\u201d custom_padding_tablet=\u201d\u201d custom_padding_phone=\u201d|56px||\u201d custom_padding_last_edited=\u201don|desktop\u201d title_font_size_tablet=\u201d45px\u201d title_font_size_phone=\u201d40px\u201d title_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 custom_css_main_element=\u201dHintergrundposition: Mitte 18% !important;\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

Lonafarnib Pr\u00e4klinisch<\/h1>\n

Arzneimittelversorgungsprogramm<\/h1>\n

 <\/p>\n

[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 use_custom_gutter=\u201don\u201d gutter_width=\u201d1\u2033 specialty=\u201don\u201d padding_left_1=\u201d35px\u201d padding_left_2=\u201d35px\u201d padding_2_tablet=\u201d|||0px\u201d padding_2_phone=\u201d|||0px\u201d padding_2_last_edited=\u201don|desktop\u201d module_class_1=\u201dsidebar-secondary-nav\u201d module_class=\u201dhandprint-bg\u201d _builder_version=\u201d4.16\u2033 background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/blue-handprint-only.png\u201d parallax=\u201don\u201d parallax_method=\u201doff\u201d inner_width=\u201d100%\u201d inner_max_width=\u201d100%\u201d custom_padding=\u201d0|0px|54px|0px|false|false\u201d z_index_tablet=\u201d500\u2033 border_width_top=\u201d10px\u201d border_color_top=\u201d#8fd2ed\u201d use_custom_width=\u201dan\u201d width_unit=\u201daus\u201d custom_width_percent=\u201d100%\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_sidebar area=\u201det_pb_widget_area_14\u2033 disabled_on=\u201dan|an|aus\u201d module_class=\u201dUnterseiten-Seitenleisten\u201d _builder_version=\u201d4.16\u2033 animation_style=\u201dverblassen\u201d z_index_tablet=\u201d500\u2033 border_width_right=\u201d5px\u201d gesperrt=\u201daus\u201d global_colors_info=\u201d{}\u201d]
\n[\/et_pb_sidebar][\/et_pb_column][et_pb_column Typ=\u201d3_4\u2033 Spezialspalten=\u201d3\u2033 _builder_version=\u201d4.16\u2033 benutzerdefiniertes_Padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d benutzerdefiniertes_Padding__hover=\u201d|||\u201d][et_pb_row_inner _builder_version=\u201d4.16\u2033 Hintergrundfarbe=\u201d#00b2e2\u2033 benutzerdefinierter_Margin=\u201d41px||\u201d benutzerdefinierter_Margin_Tablett=\u201d0px||\u201d custom_margin_phone=\u201d\u201d custom_margin_last_edited=\u201dam|Telefon\u201d custom_padding=\u201d39.4375px|20px|0|20px|false|true\u201d animation_style=\u201dFolie\u201d animation_direction=\u201doben\u201d animation_intensity_slide=\u201d25%\u201d box_shadow_style=\u201dpreset1\u2033 box_shadow_blur=\u201d38px\u201d box_shadow_spread=\u201d-12px\u201d gesperrt=\u201daus\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text admin_label=\u201dLonafarnib f\u00fcr Forschung verf\u00fcgbar\u201d _builder_version=\u201d4.18.1\u2033 header_2_line_height=\u201d1.2em\u201d background_layout=\u201ddark\u201d custom_margin=\u201d||35px\u201d custom_padding=\u201d|50px||\u201d custom_padding_tablet=\u201d|50px||50px||true\u201d custom_padding_phone=\u201d\u201d custom_padding_last_edited=\u201dauf|Desktop\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d\u201d header_font_size_last_edited=\u201dauf|Desktop\u201d header_2_font_size_tablet=\u201d25px\u201d header_2_font_size_phone=\u201d\u201d header_2_font_size_last_edited=\u201dauf|Tablet\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d19px\u201d header_4_font_size_last_edited=\u201dauf|Telefon\u201d header_4_line_height_tablet=\u201d\u201d header_4_line_height_phone=\u201d1.2em\u201d header_4_line_height_last_edited=\u201dauf|Telefon\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

Lonafarnib f\u00fcr Forschungszwecke verf\u00fcgbar<\/strong><\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=\u201dam|Telefon\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d|35px|0|0px|false|false\u201d custom_padding_tablet=\u201d|35px||35px||true\u201d custom_padding_phone=\u201d\u201d animation_direction=\u201doben\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text disabled_on=\u201dan|an|\u201d admin_label=\u201dText + Bild\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201dan|telefon\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

\"\"PRF stellt der Forschungsgemeinschaft den Farnesyltransferase-Hemmer Lonafarnib zur Verf\u00fcgung. Unser Ziel ist es, pr\u00e4klinische Studien zu unterst\u00fctzen, um die Auswirkungen von Lonafarnib auf Progerie weiter zu untersuchen.<\/p>\n

PRF hat es sich zur Aufgabe gemacht, bessere Behandlungsmethoden und Heilmittel f\u00fcr Kinder mit Progerie zu finden. Lonafarnib hat sich klinisch als hilfreich f\u00fcr einige Aspekte der Krankheit erwiesen (Gordon et al., PNAS, 2012) und verl\u00e4ngert auch die Lebenserwartung (Gordon et al., Circulation, 2014) (Gordon et al., JAMA, 2018), ist aber nicht heilend. Da neue Verbindungen identifiziert werden, die das Potenzial haben, HGPS zu lindern, gehen wir davon aus, dass diese Verbindungen in Kombination mit Lonafarnib in vitro und in Tiermodellen getestet werden m\u00fcssen.<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261\u00d7300.jpg\u201d align=\u201dcenter\u201d align_tablet=\u201dcenter\u201d align_phone=\u201d\u201d align_last_edited=\u201don|desktop\u201d disabled_on=\u201d||on\u201d admin_label=\u201dBild (nur mobil)\u201d _builder_version=\u201d4.16\u2033 z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d][\/et_pb_image][et_pb_text disabled_on=\u201doff|off|on\u201d admin_label=\u201dText (nur mobil)\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201dam|Telefon\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

PRF stellt der Forschungsgemeinschaft den Farnesyltransferase-Hemmer Lonafarnib zur Verf\u00fcgung. Unser Ziel ist es, pr\u00e4klinische Studien zu unterst\u00fctzen, um die Auswirkungen von Lonafarnib auf Progerie weiter zu untersuchen.<\/p>\n

PRF hat es sich zur Aufgabe gemacht, bessere Behandlungsmethoden und Heilmittel f\u00fcr Kinder mit Progerie zu finden. Lonafarnib hat sich klinisch als hilfreich f\u00fcr einige Aspekte der Krankheit erwiesen (Gordon et al., PNAS, 2012) und hat auch Einfluss auf die gesch\u00e4tzte Lebensdauer (Gordon et al., Circulation, 2014) (Gordon et al., JAMA, 2018), ist aber nicht heilend. Da neue Verbindungen identifiziert werden, die das Potenzial haben, HGPS zu lindern, gehen wir davon aus, dass diese Verbindungen in Kombination mit Lonafarnib in vitro und in Tiermodellen getestet werden m\u00fcssen.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=\u201dam|Telefon\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d|35px|0|0px|false|false\u201d custom_padding_tablet=\u201d|35px||35px||true\u201d custom_padding_phone=\u201d\u201d animation_direction=\u201doben\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text disabled_on=\u201don|on|\u201d admin_label=\u201dTechnische Hinweise\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 box_shadow_horizontal_tablet=\u201d0px\u201d box_shadow_vertical_tablet=\u201d0px\u201d box_shadow_blur_tablet=\u201d40px\u201d box_shadow_spread_tablet=\u201d0px\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

Technische Hinweise<\/strong><\/h4>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-solubility.pdf” button_text=”Solubility PDF” admin_label=”Solubility PDF Button” _builder_version=”4.16″ background_layout=”dark” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-administration-to-mice.pdf” button_text=”Administration PDF” admin_label=”Admin pdf button” _builder_version=”4.16″ background_layout=”dark” custom_margin=”20px|||” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner column_structure=”1_2,1_2″ custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_margin=”39px||” custom_padding=”0|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_direction=”right” global_colors_info=”{}”][et_pb_column_inner type=”1_2″ saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Ordering Information” _builder_version=”4.27.5″ header_4_line_height=”1.2em” hover_enabled=”0″ header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Bestellinformationen<\/b><\/h4>\n

Das Material wird kostenlos zur Verf\u00fcgung gestellt. Der Empf\u00e4nger tr\u00e4gt alle Versandkosten. Um Lonafarnib zu erhalten, f\u00fcllen Sie bitte einen Antrag und eine Materialtransfervereinbarung aus und senden Sie diese an wnorris@brownhealth.org<\/a><\/p>\n

Anwendung und Vereinbarung<\/a><\/p>\n

Materialtransfervereinbarung f\u00fcr nichtstaatliche Institutionen**<\/a><\/p>\n

**<\/strong>\u00a0PRF verfolgt eine Politik der\u00a0keine \u00c4nderungen an unserem MTA<\/strong>.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][et_pb_column_inner type=\u201d1_2\u2033 saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|20px|30px|20px\u201d custom_padding_tablet=\u201d|0px||0px\u201d custom_padding_phone=\u201d||30px\u201d custom_padding_last_edited=\u201don|desktop\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/FTI-graph.jpg\u201d align=\u201dcenter\u201d align_tablet=\u201dcenter\u201d align_phone=\u201d\u201d align_last_edited=\u201dauf|Desktop\u201d _builder_version=\u201d4.16\u2033 animation_style=\u201dFolie\u201d animation_direction=\u201drechts\u201d animation_intensity_slide=\u201d25%\u201d global_colors_info=\u201d{}\u201d]
\n[\/et_pb_image][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_padding=”25px|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_style=”slide” animation_direction=”right” animation_intensity_slide=”25%” border_width_top=”10px” border_color_top=”#8fd2ed” border_width_bottom=”10px” border_color_bottom=”#29327a” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Contacts for Questions and Assistance:” _builder_version=”4.27.2″ header_4_line_height=”1.2em” header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}”]<\/p>\n

Kontakte f\u00fcr Fragen und Hilfe:<\/strong><\/h4>\n

Hauptforscher: Leslie B. Gordon, MD, PhD;\u00a0lgordon@progeriaresearch.org<\/a><\/p>\n

PRF Zell- und Gewebebank: Wendy Norris; wnorris@brownhealth.org<\/a><\/p>\n

F\u00fcr US-Bundesbeh\u00f6rden oder Fragen wenden Sie sich bitte an Wendy Norris, Koordinatorin der Forschungsstudien, unter wnorris@brownhealth.org<\/a>\u00a0oder 401 274-1122 x 48063<\/span>.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 module_class=\u201dfooter\u201d _builder_version=\u201d4.21.0\u2033 background_color=\u201d#29327a\u201d custom_margin=\u201d-2px|||||\u201d custom_padding=\u201d0|0px|0|0px|false|false\u201d z_index_tablet=\u201d500\u2033 border_width_top=\u201d12px\u201d border_color_top=\u201d#00b2e2\u2033 global_module=\u201d133\u2033 locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_row column_structure=\u201d1_4,1_4,1_2\u2033 make_equal=\u201don\u201d module_class=\u201d et_pb_row_fullwidth\u201d _builder_version=\u201d4.16\u2033 width=\u201d89%\u201d width_tablet=\u201d80%\u201d width_phone=\u201d\u201d width_last_edited=\u201don|desktop\u201d max_width=\u201d89%\u201d max_width_tablet=\u201d80%\u201d max_width_phone=\u201d\u201d max_width_last_edited=\u201dauf|Desktop\u201d z_index_tablet=\u201d500\u2033 make_fullwidth=\u201dan\u201d width_unit=\u201daus\u201d custom_width_percent=\u201d100%\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_cta button_url=\u201dhttps:\/\/lp.constantcontactpages.com\/sl\/88gWWwz\u201d button_text=\u201dJetzt anmelden\u201d admin_label=\u201dF\u00fcr Updates anmelden\u201d module_class=\u201dsign-btn\u201d _builder_version=\u201d4.27.4\u2033 header_font_size=\u201d25px\u201d background_color=\u201d#29327a\u201d animation_style=\u201dslide\u201d animation_direction=\u201dleft\u201d animation_intensity_slide=\u201d25%\u201d link_option_url=\u201dhttps:\/\/lp.constantcontactpages.com\/sl\/88gWWwz\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d30px\u201d header_font_size_last_edited=\u201dan|desktop\u201d z_index_tablet=\u201d500\u2033 border_radii=\u201dan|25px|25px|25px|25px\u201d global_colors_info=\u201d{}\u201d button_bg_color__hover_enabled=\u201dan\u201d button_bg_color__hover=\u201d#8fd2ed\u201d button_border_color__hover_enabled=\u201dan\u201d]<\/p>\n

Melden Sie sich an<\/h2>\n

f\u00fcr unsere<\/h2>\n

Neuigkeiten!<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_cta button_url=\u201dhttps:\/\/progeriaresearch.donorsupport.co\/-\/XZHJVWZR\u201d button_text=\u201dJetzt spenden\u201d admin_label=\u201dGemeinsam werden wir die Heilung finden!\u201d module_class=\u201dsign-btn\u201d _builder_version=\u201d4.16\u2033 header_font_size=\u201d25px\u201d background_color=\u201d#29327a\u201d animation_style=\u201dslide\u201d animation_direction=\u201dleft\u201d animation_intensity_slide=\u201d25%\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d30px\u201d header_font_size_last_edited=\u201don|desktop\u201d body_font_size_tablet=\u201d\u201d body_font_size_phone=\u201d\u201d body_font_size_last_edited=\u201don|desktop\u201d z_index_tablet=\u201d500\u2033 border_radii=\u201don|25px|25px|25px|25px\u201d global_colors_info=\u201d{}\u201d button_bg_color__hover_enabled=\u201don\u201d button_bg_color__hover=\u201d#8fd2ed\u201d button_border_color__hover_enabled=\u201dein\u201d]<\/p>\n

Gemeinsam<\/h2>\n

WILLE<\/em><\/h2>\n

Finde die Heilung!<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2026\/03\/2026-footer-image-copy.png” title_text=”2026 footer image copy” _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”35px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

[et_pb_section fb_built=\u201d1\u2033 fullwidth=\u201don\u201d disabled_on=\u201doff|off|off\u201d _builder_version=\u201d4.16\u2033 border_width_bottom=\u201d55px\u201d border_color_bottom=\u201d#29327a\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_fullwidth_header _builder_version=\u201d4.18.1\u2033 title_font=\u201d||||||||\u201d title_font_size=\u201d55\u2033 background_color=\u201d#29327a\u201d background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg\u201d background_position=\u201dcenter_left\u201d custom_padding=\u201d9vw||9vw||true\u201d custom_padding_tablet=\u201d\u201d custom_padding_phone=\u201d|56px||\u201d custom_padding_last_edited=\u201don|desktop\u201d title_font_size_tablet=\u201d45px\u201d title_font_size_phone=\u201d40px\u201d title_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 custom_css_main_element=\u201dHintergrundposition: Mitte 18% !important;\u201d global_colors_info=\u201d{}\u201d] Lonafarnib - Pr\u00e4klinisches Arzneimittelversorgungsprogramm [\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 use_custom_gutter=\u201don\u201d gutter_width=\u201d1\u2033 specialty=\u201don\u201d padding_left_1=\u201d35px\u201d padding_left_2=\u201d35px\u201d padding_2_tablet=\u201d|||0px\u201d padding_2_phone=\u201d|||0px\u201d padding_2_last_edited=\u201don|desktop\u201d module_class_1=\u201dsidebar-secondary-nav\u201d module_class=\u201dhandprint-bg\u201d _builder_version=\u201d4.16\u2033 background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/blue-handprint-only.png\u201d Parallaxe = \u201eein\u201c Parallaxmethode = \u201eaus\u201c innere Breite = \u201e100%\u201c innere maximale Breite = \u201e100%\u201c benutzerdefinierte Polsterung = \u201e0|0px|54px|0px|false|false\u201c z_index_tablet = \u201e500\u2033 border_width_top = \u201e10px\u201c [\u2026]<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\t\t\t\t[vc_row][vc_column][vc_custom_heading text=\"Lonafarnib Pre-clinical Drug Supply Program\" font_container=\"tag:h1|text_align:center\" use_theme_fonts=\"yes\"][vc_column_text]July 2015: Lonafarnib Now Available for Research<\/strong>\r\n\r\nPRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\r\n\r\nIt is PRF's steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012)\u00a0as well as influence increased estimated lifespan, (Gordon et al, Circulation, 2014)\u00a0but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.\r\n\r\nMany thanks to the pharmaceutical company Merck for making this program possible.<\/strong>\r\n\r\nOrdering Information<\/b>\r\n\r\nThe material is supplied at no cost.\u00a0 Recipient pays for all shipping charges.\r\n\r\nTo receive lonafarnib, please fill out an application and material transfer agreement, and submit to joan_brazier@brown.edu<\/a>\r\n\r\n<\/a>Application and Agreement<\/a>\r\n\r\nMaterial Transfer Agreement for Non-government Institutions<\/a>**\r\n\r\n**<\/strong> PRF has a policy of no changes to our MTA<\/strong>.\r\n\r\n<\/strong>\r\n\r\nContacts for Questions and Assistance:<\/strong>\r\n\r\nPrincipal Investigator: Leslie B. Gordon, MD, PhD; lgordon@progeriaresearch.org<\/a>\r\n\r\nResearch Study Coordinator: Joan Brazier; joan_brazier@brown.edu<\/a>\r\n\r\nFor U.S. Federal Government Institutions or questions, please contact Joan Brazier, Research Study Coordinator, at joan_brazier@brown.edu<\/a> or 401-863-9628.[\/vc_column_text][\/vc_column][\/vc_row]\t\t","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-790","page","type-page","status-publish","hentry"],"yoast_head":"\nLonafarnib drug supply | The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/de\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lonafarnib drug supply | The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/de\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T15:43:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"497\" \/>\n\t<meta property=\"og:image:height\" content=\"572\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\",\"name\":\"Lonafarnib drug supply | The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"datePublished\":\"2017-02-26T19:12:39+00:00\",\"dateModified\":\"2026-03-17T15:43:56+00:00\",\"description\":\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lonafarnib Pre-clinical Drug Supply Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lonafarnib drug supply | The Progeria Research Foundation","description":"PRF stellt der Forschungsgemeinschaft den Farnesyltransferase-Hemmer Lonafarnib zur Verf\u00fcgung. Unser Ziel ist es, pr\u00e4klinische Studien zu unterst\u00fctzen, um die Auswirkungen von Lonafarnib auf Progerie weiter zu untersuchen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/de\/lonafarnib-pre-clinical-drug-supply-program\/","og_locale":"de_DE","og_type":"article","og_title":"Lonafarnib drug supply | The Progeria Research Foundation","og_description":"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/de\/lonafarnib-pre-clinical-drug-supply-program\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_modified_time":"2026-03-17T15:43:56+00:00","og_image":[{"width":497,"height":572,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@Progeria","twitter_misc":{"Est. reading time":"4 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","url":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","name":"Lonafarnib drug supply | The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","datePublished":"2017-02-26T19:12:39+00:00","dateModified":"2026-03-17T15:43:56+00:00","description":"PRF stellt der Forschungsgemeinschaft den Farnesyltransferase-Hemmer Lonafarnib zur Verf\u00fcgung. Unser Ziel ist es, pr\u00e4klinische Studien zu unterst\u00fctzen, um die Auswirkungen von Lonafarnib auf Progerie weiter zu untersuchen.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Lonafarnib Pre-clinical Drug Supply Program"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Die Progeria Research Foundation","description":"F\u00fcr die Kinder \u2665 F\u00fcr die Heilung","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Die Progeria Research Foundation","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/pages\/790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/comments?post=790"}],"version-history":[{"count":2,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/pages\/790\/revisions"}],"predecessor-version":[{"id":21465,"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/pages\/790\/revisions\/21465"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/de\/wp-json\/wp\/v2\/media?parent=790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}